Testing HRS-9813 for progressive pulmonary fibrosis
Part of Lungs & breathing clinical trials.
This trial tests a new drug called HRS-9813 for people with pulmonary fibrosis (scarring in the lungs) that continues to worsen. It looks at whether the drug can slow down the disease compared to a placebo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 21 or older (for PPF) or 45 or older (for IPF) and have a confirmed diagnosis of pulmonary fibrosis.
- You have had a lung function test showing your FVC is at least 40% of normal and your DLCO is at least 25% of normal.
- If you were taking nintedanib or pirfenidone, you either stopped at least 8 weeks ago or have been on a stable dose for at least 8 weeks.
- You have not had a lung infection, a flare-up of your lung disease, or a hospitalization for heart or lung problems in the last 3 months.
- You do not have severe emphysema, active tuberculosis, uncontrolled heart disease, or a history of lung transplant or certain cancers in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called AK3280 to see if it can help people with idiopathic pulmonary fibrosis (a lung disease that causes scarring). It aims to slow down the worsening of lung function. If you have IPF and haven't been treated with anti-fibrotic drugs recently, you might be able to join.
This trial tests a new tablet, HEC585, for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug can help improve lung function and slow the disease. Participants must have a confirmed IPF diagnosis and meet specific breathing test results.
This Phase 2 study tests whether HEC585 can slow the decline in lung function in people with progressive fibrosing interstitial lung disease (PF-ILD). It may help preserve breathing capacity and breathing tolerance over time.
This trial tests a new medication called SC1011 taken twice a day, compared to a placebo, to see if it can help people with IPF. It is for patients who were diagnosed within the last 5 years and have moderate lung function.
This trial is testing a new medication called HSK50042 to see if it can help people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. If you have IPF and meet some basic health criteria, you might be able to join.
This study tests an experimental medicine called HSK44459 to see if it can slow down progressive pulmonary fibrosis (PPF), a condition that causes lung scarring and breathing difficulty. The goal is to learn if the medicine can help people keep more of their lung function compared to a placebo.
Hear when a new IPF and PPF trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.